2 not yet recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow ABI-6250: new trials by email Literature Review of ABI-6250 trials Research Report on ABI-6250
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function ABI-6250 - Mild Hepatic Imparement | Phase 1 | Not yet recruiting | Assembly Biosciences | 20 | 2026-10-01 | 2026-10-16 |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection ABI-6250 - Chronic Hepatitis D Infection | Phase 2 | Not yet recruiting | Assembly Biosciences | 80 | 2026-10-01 | 2026-08-13 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants ABI-6250, Placebo - Hepatitis Delta Virus, Hepatitis D | Phase 1 | Completed | Assembly Biosciences | 40 | 2025-01-31 | 2025-12-04 |
Hepatitis D (1)
New Zealand (3) · France (1) · Georgia (1) · Germany (1) · Italy (1) · Moldova (1) · Pakistan (1) · Romania (1) · Spain (1) · Ukraine (1) · United Kingdom (1)